PBESProceedings of Business and Economic Studies2209-26412209-265XBio-Byword Scientific Publishing Pty. Ltd.10.26689/pbes.v9i6.15441ArticleResearch on Financial Dilemmas and Breakthroughs of Chinese Pharmaceutical Enterprises: Taking Dizhe Pharmaceuticals as an Examplehttps://artdesignp.com/journal/PBES/9/6/10.26689/pbes.v9i6.15441MaoRongyan,ZhangXinling2026962026-07-14In recent years, the pharmaceutical industry has witnessed frequent policy adjustments, intensifying market competition and continuous growth in R&D investment. Innovative pharmaceutical enterprises are generally under great financial pressure. As a typical innovative drug R&D enterprise, Dizhe Pharmaceuticals inevitably faces difficulties such as capital shortage, high R&D investment, and slow commercialization. Adopting the combined method of case analysis and financial indicator analysis, this paper systematically sorts out the financial breakthrough paths of Dizhe Pharmaceuticals. The research concludes that Dizhe Pharmaceuticals relieves financial pressure and resists financial risks through pipeline focus, accelerated commercialization, capital structure optimization, and external strategic collaboration, and effectively improves its long-term value creation capability. This case provides a reference for similar innovative pharmaceutical enterprises.

Li H, Zhang M, 2024, Research on Financial Dilemmas and Financing Strategies of Innovative Pharmaceutical Enterprises. Accounting Research, (6): 78–89.

Wang Z, Chen X, 2023, Research on the Relationship Among R&D Investment, Capital Structure and Financial Performance of Biomedical Enterprises. Chinese Journal of Pharmaceutical Industry, 54(10): 1523–1530.

Wang Y, 2024, Research on Valuation Methods of Unlisted Biomedical Enterprises on STAR Market, Zhongnan University of Economics and Law, June 1, 2024.

Kaplan RS, Norton DP, 1992, The Balanced Scorecard. Harvard Business Review, 70(1): 71–79.

Fu S, 2025, Chairman of Dizhe Pharmaceuticals: Adhering to Original Innovation and Facing Global Competition, China Securities Journal, July 16, 2025.

Meng P, 2025, Dizhe Pharmaceuticals: Focusing on Advantageous Fields and Realizing R&D and Commercialization Cycle, China Securities Journal, February 21, 2025.

Zhang L, Zhou T, 2024, Valuation Model and Financial Risk Identification of STAR Market Innovative Pharmaceutical Enterprises. Securities Market Herald, (9): 32–41.